B
BiomeBank
A clinical stage biotechnology company developing microbial therapies
About BiomeBank
BiomeBank is a leading microbiome therapeutics company with a mission to restore human gut microbial ecology. BIOMICTRA,TM is the first approved donor derived microbiome therapy in the world (approved by TGA in 2022 for C.difficile infection). BiomeBank’s CONSORTIOMETM drug development platform, leverages data from BIOMICTRA use in discovery trials in novel disease indications to create therapies disease specific cultured microbiome based therapies. The CONSORTIOME TM platform contains the ability to co-culture >100 of the most prevalent species covering >90% of known gene families in a healthy human gut microbiome into one drug substance. Cultured therapy BB265 has been designed to treat ulcerative colitis and will enter a phase 1b/2a human study in 2025. Due to similar disease mechanisms, BB265 is expected to also have efficacy in treating Crohn’s disease. In addition, BB128 is being positioned for orphan disease indicaton and discovery trials are underway in 4 other novel disease indications.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | Apr 2026 | $9.7M | $45M | Blackmores | ↗ |
| SECONDARY✓Other financing | Mar 2024 | $3.9M | — | South Australian Venture Capital Fund · Artesian Capital Management | — |
Growth signals
Latest recorded traffic for BiomeBank is 5.1K monthly website visits, up 59.4% over the last three months. BiomeBank's team grew 2.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
BiomeBank in the Adelaide ecosystem
The BiomeBank office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- TFThe Hospital Research Foundation
Government of South Australia
Innovation Connections
Series A4 investors entered at this stage
Artesian Capital Management
Ellerston Capital
South Australian Venture Capital Fund
Chapman Capital Partners
Series B and later1 investor entered at this stage
Blackmores
Other known investors1 additional known investor
University of Adelaide
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BiomeBank on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BiomeBank’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









